A study to investigate the effects of AZD0901 monotherapy in adult participants with 2L+ advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2 - GAMBIT

Inclusion Criteria

• Inclusion Criteria:
• - Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus, with positive CLDN18.2 expression.
• - Disease progression on or after at least one prior regimen for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease.
• - Must have at least one measurable lesion assessed by the Investigator based on RECIST 1.1.
• - ECOG performance status of 0 or 1.
• - Minimum life expectancy of ≥12 weeks.
• - Adequate organ and bone marrow function.
• - Minimum body weight of 40 kg.
• - Sex and Contraceptive Requirements.
• Exclusion Criteria:
• - Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH +.
• - Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers.
• - CNS metastases or CNS pathology.
• - Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations).
• - Persistent toxicities (CTCAE Grade ≥2) caused by previous anticancer therapy.
• - History of thromboembolic events.